pipette
ENEnglish

A SARS-CoV-2 entry inhibitor trimerizes to lock the spike protein in a closed conformation

Huihui Mou, Bo Gao, Gang Ye, Divyasha Saxena, Lizhou Zhang, Fan Bu, Jyoti Vishwakarma, Yulia Getmanenko, Shuo Zhou, Claudia Ruiz Bayona, Lin Li, Janarjan Bhandari, Charles C. Bailey, Gogce C. Crynen, Claire E. Kitzmiller, Hao Li, Yuka Otsuka, Lalit Batra, Stuart M. Weston, Matthew B. Frieman, David Kyle Meyerholz, Louis D. Scampavia, Timothy Spicer, Reuben S. Harris, Michael D. Cameron, Thomas D. Bannister, Jian Zheng, Michael Farzan, Fang Li, Hyeryun Choe

Revista con revisión por paresUso en el mundo real

En palabras de los autores

Abstract The SARS-CoV-2 spike protein binds its receptor ACE2 to initiate target-cell infection. To engage ACE2, at least one of the three receptor-binding domains (RBDs) of the spike must adopt the up orientation. Here, we describe S22, a potent, bioavailable, and non-toxic inhibitor of BA.2 and all subsequent Omicron variants. Cryo-EM analyses showed that S22 assembled as a trimer in the central cavity of the spike apex, stabilizing all three RBDs in the down orientation, thereby preventing ACE2 association. Binding studies, especially those using mixed S22-sensitive and -resistant spikes, imply a cooperative assembly of three S22 molecules with three RBDs, resulting in an unusually slow S22 off-rate. Consistent with its slow dissociation and favorable pharmacokinetics, S22 suppressed viral replication and inflammation in the lungs of XBB.1.5-infected female mice. Thus, S22 potently inhibits Omicron entry through a distinct mechanism whereby a small compound assembles cooperatively as a trimer to stabilize spike in an inactive conformation.

Resultado principalEl resumen no menciona limitaciones.

Apareció: jueves, 29 de octubre. Nature Communications. Revista con revisión por pares.

DOI: 10.1038/s41467-026-78835-9